Evidence against a major role of adenosine in oxygen-dependent regulation of erythropoietin in rats  by Gleiter, Christoph H. et al.
Kidney International, Vol. 52 (1997), pp. 338—344
Evidence against a major role of adenosine in oxygen-dependent
regulation of erythropoietin in rats
CHRISTOPH H. GLEITER, MATHIAS BRAUSE, URSULA DELABAR, HUBERT ZEBSKI, and KAI-UwE ECKARDT
Abteilung Klinische Pharmakologie, Georg-August-Universitat, Gottingen; Abteilung Innere Medizin mit Schwerpunkt Nephrologie und
Intensivmedizin, Virchow-Klinikum, Humboldt-Universität, Berlin; Pharmakologisches Institut, Eberhard-Karls-Universität Tubingen,
Tubingen, Germany
Evidence against a major role of adenosine in oxygen-dependent
regulation of erythropoietin in rats. This in vivo study investigated
whether adenosine (ADO) plays a role in oxygen-dependent production of
erythropoietin (EPO). Exposure of rats to 0.075% carbon monoxide (CO)
for four hours was used as a stimulus for EPO production. To inhibit
potential effects of ADO, rats were treated with the non-specific ADO
antagonist theophylline, the selective ADO Al receptor blockers DPCPX
and KW-3902, the selective ADO A2 receptor blocker DMPX, and
AOPCP, an inhibitor of 5'-ectonucleotidasc, an ADO generating enzyme
that is expressed on the surface of EPO producing cells. To stimulate
ADO receptor activity, animals were treated with the selective ADO Al
and A2 receptor agonists CHA and CGS 21680, the ADO reuptake
inhibitors dipyridamole and soluflazine and the ADO desaminase inhibi-
tor EHNA. At doses known to interfere with ADO signal transmission in
vivo, none of these substances either influenced EPO serum levels in
normoxic rats or affected the approximately 30-fold rise in EPO serum
levels and the increase in renal EPO mRNA after exposure to carbon
monoxide. Continuous administration of theophylline to normoxic rats for
seven days did not alter hematocrit, hemoglobin or EPO serum levels.
Taken together, these experiments do not support the hypothesis that
ADO plays an important role in the regulation of EPO production.
A major physiological mechanism by which mammals respond
to hypoxia is through stimulation of erythropoiesis, which results
in an increased blood oxygen-carrying capacity. This response is
mediated by oxygen-dependent production of the glycoprotein
hormone erythropoietin (EPO) in liver and kidneys [1, 2]. The
major control of EPO production occurs at the level of its mRNA
and involves changes in EPO gene transcription rate [3]. An
enhancer sequence has been identified that mediates hypoxia-
induced activation of EPO gene activity, and nuclear proteins
binding to this sequence are identified [4—7]. However, the
cellular mechanisms by which hypoxia is sensed remain unknown.
Recently, peritubular renal fibroblasts and perisinusoidal Ito
cells have been identified as the renal and one of the hepatic cell
populations producing EPO [8—10]. A common characteristic of
these cells used for their identification is the expression of
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5' -nucleotidase on their surface, which splits adenosine mono-
phosphate (AMP) into adenosine (ADO) and phosphate [11, 12].
ADO has since long been postulated to be a modulator of EPO
production [131. Indeed, renal interstitial levels of adenosine were
reported to increase in response to increased tubular workload or
decreased oxygen supply [14, 15], and an increase of ADO results
in hemodynamic changes [16].
The effect of ADO on EPO production in vivo has not been
directly investigated thus far, but a potentially important role of
ADO has been inferred from studies in human hepatoma cells,
used as an in vitro model of EPO production, and from studies
measuring erythropoiesis in polycythemic mice [13]. Also, in
patients with post-transplant erythrocytosis that may be due to
inappropriate EPO production, the non-specific ADO antagonist
theophylline was found to reduce EPO levels and hematocrit [17].
In contrast, adding the non-selective ADO agonist N6-ethyl-
carboxamidoadenosine or forskolin, which generates the second
messenger cyclic AMP, to the perfusate of isolated perfused rat
kidneys did not alter the oxygen dependent production of EPO
[181 and EPO mRNA [19].
In view of these contradictory findings, and that selective ADO
Al and A2 receptor agonists and antagonists as well as other
compounds that potentially alter interstitial ADO availability have
recently become available, we used such compounds to examine
the role of ADO for EPO formation in normoxic and hypoxic rats.
METHODS
Animals
Male Wistar rats weighing 200 to 280 g were kept on a regular
12-hour dark-light cycle with free access to food and water. All
animals were handled for three to five days before the studies
were performed. The experiments were approved by the Animal
Care and Use Committee of the University of Gottingen.
Compounds and solvents
The following compounds were used and dissolved in 0.85%
NaCl unless otherwise indicated: theophylline (Euphyllin 200®; a
gift of Byk Gulden GmbH, Konstanz, Germany); DPCPX (9-
Cyclopentyl-l,3-dipropylxanthine; RBI, Natick, MA, USA) dis-
solved in saline, ethanol, and DMSO in a relation of 2:1:1;
KW-3902 [8-(3-noradamantyl-1,3-dipropylxanthine)] (a gift of
Kyowa Hakko Kogyo Co., Ltd., Düsseldorf, Germany), dissolved
in saline containing 1% vol/vol DMSO and 1% vol/vol 1 NNaOH;
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DMPX (3,7-dimethyl-1-propargylxanthine; RBI), dissolved in sa-
line containing 10% ethanol; AOPCP (a,/3-methyleneadenosine
5'-diphosphate; Sigma-Aldrich Chemie GmbH, Deisenhofen,
Germany); CHA (N6-cyclohexyladenosine; Sigma-Aldrich); CGS
21680 (2-[p-(2-carboxyethyl)phenetylamino]-5 -N-ethylcarboxam-
idoadenosine) (a gift of Ciba-Geigy Corporation, Summit, NJ,
USA); dipyridamole (Persantin®; Dr. Karl Thomae GmbH,
Biberach/Ri, Germany); R 64719 (soluflazine; a gift of Janssen
Research Foundation, Beerse, Belgium); EHNA, (erythro-9--(2-
hydroxy-3-nonyl)adenine hydrochloride), RBI. When necessary,
thiopental (Trapanal®, Byk Gulden GmbH) was used as an
anesthetic.
Experiments
Functional anemia caused by normobaric carbon monoxide
inhalation was used as a stimulus for EPO production using a
technique reported earlier [20]. Together with a control group,
treated animals were exposed in a plexiglass chamber for four
hours to a gas mixture of 0.075% CO in synthetic air (Messer
Griesheim, Duisburg, Germany). Each animal received a single
dose (in mg/kg body wt) of the respective compound i.p. 15
minutes before being exposed to hypoxia in the chamber. The only
exception was AOPCP, which was injected i.m. 90 minutes prior
to the exposure to CO. Groups of up to six animals treated with
a particular drug were exposed to hypoxia together with controls,
which were treated with the same volume of the respective solvent
as the actively treated animals. Within 15 minutes after the end of
exposure to this gas mixture the animals were decapitated and the
trunk blood collected. Immediately thereafter, the left kidney was
taken and frozen in liquid nitrogen for mRNA extraction. Serum
and tissue samples were kept at —80°C until analysis.
Some compounds were also given under normoxic conditions
(ambient air) to study their effects on basal EPO production.
In a second experiment, a long-term treatment with theophylline
and placebo (0.85% saline) was carried out. A theophylline infusion
rate of 2 mg/kg/hr over seven days was achieved by implanting 2
Aizet® osmotic pumps (Model 2ML1; Charles River, Sulzfeld,
Germany) subcutaneously in the back. At the end of this experiment
the animals were bled for determination of EPO and theophylline
concentrations as well as hemoglobin and hematocrit.
In a separate set of experiments, renal tissue ADO levels were
measured under normoxic conditions and under CO exposure in
untreated control animals and animals treated with AOPCP,
EHNA, soluflazine and dipyridamole (5 animals each), as de-
scribed [14]. Animals exposed to CO received thiopental (80
mg/kg i.p.) a few minutes before the end of the four hour exposure
and were then returned on a heating table placed in the chamber,
which was subsequently flushed to re-achieve the CO atmosphere.
When anesthesia was effective animals were quickly removed
from the chamber, laparotomized and the left kidney gently
mobilized, removed and frozen within 1 to 3 seconds with a
Wollenberger-clamp precooled in liquid nitrogen [14]. These
kidneys were then kept in liquid nitrogen until homogenization
for ADO analysis.
Assays
Eiythropoietin. Serum EPO concentrations were determined by
radioimmunoassay as described earlier [21] with the use of a
rabbit antiserum raised against pure recombinant human EPO
and iodinated human EPO (Amersham International) as a tracer.
A rat serum pooi enriched in EPO was prepared by exposing
donor animals to hypoxia and was used as standard after calibra-
tion against the II International Reference Preparation by In Vivo
Bioassay. Samples from one experiment were always analyzed in
parallel in the same assay.
EPO-mRNA. In selected animals total renal RNA was prepared
using an acid guanidinium thiocyanate-phenol-chloroform extrac-
tion method [22]. EPO mRNA was measured by RNAse protec-
tion as previously described [23]. An RNA probe was continuously
labeled from a genomic rat EPO DNA template (PstI/SacI
fragment containing 132 bp of exon V and approximately 300 bp
of the adjoining intron (kindly provided by Dr. P.J. Ratcliffe,
Oxford, UK) using SP 6 polymerase and alpha 32P-GTP (410
Ci/mmol; Amersham, UK). In brief, 100,230 g of total RNA was
hybridized to 0.7 x 106 cpm of radiolabeled probe in 80%
formamide, 40 mivi piperazine-N,N'-bis(2-ethane sulfonic acid),
pH 6.4, 400 mmol/liter NaC1, 1 mivi EDTA at 60°C overnight, and
RNAse digestion was carried out at 20°C for 30 minutes. Pro-
tected fragments were separated by electrophoresis on a denatur-
ing 10% polyacrylamide gel, and visualized on a phosphorimager.
Adenosine. As described earlier [14], the frozen kidneys were
powdered under liquid nitrogen and the sample weighed. The
homogenate was then treated with 0.6 N perchloric acid at 0°C.
After adding 50 nmol methyl-adenosine (m-ADO) as internal
standard the supernatant was recovered after centrifugation and
adjusted to pH 7.2 to 7.4 with 2 M potassium carbonate. KC1O4
originating during this procedure was removed by centrifugation
and the supernatatnt filtrated. The quantitaive analysis of ADO
was performed with HPLC as described earlier [241. In brief, 2 ml
of tissue extract were applied onto phenylboronate columns
(Frankfurt am Main, Germany), washed twice with citrate buffer
solution and eluted with 0.5 ml HCI (0.1 mol/liter). A total of 50
1.d of the eluate were applied onto the HPLC system with a
reversed phase column (C 18, 3 gm). The UV absorbance
detector (Sykam, Germany) was set at 254 nm. The mobile phase
was an aquaeous solution of 0.01 mmol/liter ammonium phos-
phate and 6% methanol; increasing percentages of acetonitril
were added by a gradient system. ADO concentration was calcu-
lated by peak area corrected for internal standard peak area.
Absolute recovery of 3H-labeled ADO was 87 to 89%. Precision
of the analytical procedure (recovery of ADO added to the tissue
and calculated for internal standard) was 3% in the concentra-
tion range from 5 X iO to i0 mol/liter.
Dipyridamole. Serum samples were analyzed using an HPLC
with UV detection (280 nm) using propranolol as an internal
standard [25]. In brief, a Li Chrospher 5 j.m reversed-phase Cl 8
column was used. Dipyridamole and propranolol were eluted with
37% acetonitrile in 0.02 M phosphate buffer containing 0.01 M
tetramethylethylenediamine at pH 2.9, The calibration curve was
linear in the range of 20 to 1000 ng/ml (r = 0.9895).
Theophylline. Theophylline was measured using a fluorescence
polarization immunoassay (Tdx® Theophyllin 2; Abbott Diagnos-
tics).
Hemoglobin and hematocrit. These variables were measured
using a routine Coulter counter technique.
Statistics
Each study group and their respective controls were compared
using the Mann-Whitney test. A P value < 0.05 was considered
significant.
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Fig. 1. Effect of different doses of theophylline on serum EPO concentra-
tions in animals exposed for four days to 0.075% carbon monoxide
(controls, 0; theophylline treated animals, •). The theophylline concen-
trations at the end of the exposure to hypoxia are shown by filled lozenges.
Data represent means 5EM; N = 6 to 8 animals/group.
RESULTS
Inhibiting ADO. To inhibit ADO availability and receptor-
activity, animals were treated with the non-selective ADO recep-
tor antagonist theophylline, with selective antagonists for ADO A
1 receptors (DPCPX and KW 3902) and ADO A 2 receptors
(DMPX) and an inhibitor of 5'-ectonucleotidasc (AOPCP).
Increasing ADO. To increase ADO availability and receptor-
activity, animals were treated with ADO uptake inhibitors (dipy-
ridamole, soluflazine), an ADO deaminase inhibitor (EHNA),
and selective agonists for ADO A 1 (CHA) and ADO A 2
receptors (CGS 21680).
Effect of ADO antagonistic compounds on hypoxia-induced
EPO levels
Exposure of animals to 0.075% CO for four hours resulted in an
approximately 30-fold increase of serum EPO levels, which is in
accordance with previous studies [26]. As shown in Figure 1, treat-
ment of rats with theophylline (10 to 50 mg/kg body wt) did not have
a significant effect on EPO serum levels, although, as expected,
theophylline serum levels increased in a dose dependent fashion.
Figure 2 illustrates that the application of AOPCP, at a dose
previously demonstrated to maximally inhibit renal activity of
5'-eetonucleotidase [27], results in a slight, but statistically not
significant reduction of mean serum EPO levels.
To selectively block ADO receptors, the specific ADO A 1
receptor antagonists KW 3902 and DPCPX and the ADO A 2
receptor antagonist DMPX were used. DPCPX resulted in a slight
increase of the EPO response (not statistically significant). EPO
levels were not consistently different from controls with two doses
of KW 3902 (1 and 3 mg/kg) as well as DMPX (Figure 3).
Effect of ADO synergistic compounds on hypoxia-induced EPO
levels
Figure 4 shows that inhibition of ADO uptake with either
dipyridamole or soluflazine, or inhibition of ADO deamination by
EHNA had no effect on EPO serum levels, in dipyridamole-
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Fig. 2. Effect of the nucleotidase inhibitor (AOPCP) on serum EPO
concentration in animals exposed for four hours to 0.075% carbon
monoxide. Data represent means suM; N = 8 to 10 animals/group.
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Fig. 3. Effect of different selective adenosine receptor antagonists on
serum EPO concentrations in rats exposed for four hours to 0.075%
carbon monoxide (adenosine Al receptor antagonists, DPCPX, KW-3902;
adenosine A2 receptor antagonist, DMPX). Data represent means SEM;
N = 6 to 8 animals/group. Symbols are: (0) control; (0) ADO antagonist.
treated animals the mean dipyridamole concentration four hours
after i.p. injection was 0.25 0.3 g/ml.
To test whether selective stimulation of ADO receptors alters
the CO-induced increase in EPO levels, CHA, a selective ADO
Al receptor agonist, and CGS 21680, a selective ADO A2
receptor agonist were used. Figure 5 illustrates that neither
substance affected the EPO response.
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Fig. 4. Effect of different adenosine reuptake inhibitors (dipyridamole,
soluflazine), and the nucleosidase inhibitor (EHNA) on serum EPO
concentrations in animals exposed for four hours to 0.075% carbon
monoxide. Data represent means ScM; N = 8 to 10 animals/group.
Symbols are: (12) control; () compound.
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Fig. 5. Effect of selective adenosine receptor agonists on serum EPO
concentrations in animals exposed for four hours to 0.075% carbon
monoxide (adenosine Al receptor agonist, CHA; adenosine A2 receptor
agonist, CGS 21 680). Data represent means scM; N = 6 to 8
animals/group. Symbols are: (11) control; (D) agonist.
Effect of ADO synergistic and antagonistic compounds on EPO
levels in normoxic animals
To investigate whether inhibition or stimulation of ADO Al or
A2 receptors mimick part of the hypoxic response, theophylline,
the ADO Al and A2 antagonists KW-3902 and DMPX, and the
ADO Al and A2 agonists CHA and CGS 21680 were given to
normoxic animals and their serum EPO levels were determined
Table 1. Etythropoietin serum concentrations under normoxic
conditions (ambient air) following the i.p. application of the indicated
compounds
Compound
Dose
mg/kg
EPO concentration
mU/mi
Controls — 20 1.8
Theophylline 10 20 4.5
KW-3902 3 24 1.4
DMPX 1 23 6.0
CHA 2 21±1.5
CGS 21 680 5 23 2.1
Data are means scM; N = 6 to 8 animals/group.
four hours later. As shown in Table 1, none of the five substances
had a significant effect.
Effect of ADO synergistic and antagonistic compounds on
hypoxia-induced EPO mRNA levels
To test whether ADO synergistic or antagonistic compounds
might have opposite effects on EPO gene expression and EPO
mRNA translation under our experimental conditions, which
could result in unchanged serum EPO concentrations, renal EPO
mRNA from three animals of each group with similar serum
EPO concentrations was determined by RNAse protection. EPO
mRNA levels in kidney tissue were similar in treatment and
control groups (Fig. 6).
Effect of hypoxia and treatment with AOPCP, EHNA,
soluflazine and dipyridamole on renal tissue ADO
concentrations
As shown in Table 2, renal tissue ADO concentrations under
basal conditions were 5.95 1.03 nmol/g wet wt. This value is very
similar to the concentration reported by other investigators [14,
15]. Carbon monoxide exposure alone and treatment with
AOPCP had no demonstrable effect on tissue ADO concentra-
tions. ADO levels were increased, however, in animals treated
with the uptake inhibitors dipyridamole and soluflazine and the
deaminase inhibitor EHNA.
Effect of long-term treatment with theophylline on EPO serum
levels in normoxic rats
In view of the evidence that long-term treatment with theoph-
ylline slightly reduces EPO serum levels in healthy normoxic
humans [17], we tested the effects of continuous application of the
drug to normoxic rats for seven days by recording the serum EPO
levels, hematocrit and hemoglobin concentration. For unknown
reasons the EPO levels were slightly higher than in animals
studied under basal conditions, but there was no difference
between animals treated with theophylline and untreated controls
studied in parallel (Table 3).
DISCUSSION
Using a variety of different ADO synergistic and antagonistic
compounds in vivo we failed to demonstrate a significant effect of
ADO on EPO production under normoxic and hypoxic condi-
tions. Several lines of evidence suggest that this lack of an effect
on EPO production is not due to inappropriate dosing or the
experimental setting in which these substances were investigated.
First, the doses of all substances tested were based on earlier
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Fig. 6. Autoradiographs of RNase protection
assays for EPO mRNA in the kidneys of rats
exposed to carbon monoxide (0.075%) for four
hours and treated with the indicated
compounds rats (N = 3 animals/treatment).
There was no difference in the EPO mRNA
signal in any group of treated animals
compared with their respective controls (doses:
non-specific ADO antagonist theophylline as
indicated, 5'-ectonucleotidase inhibitor AOPCP
4 mg/kg, ADO Al receptor agonist CHA 2 mg/
kg, ADO A2 receptor agonist CGS 21680 1 mg/
kg, ADO Al receptor antagonist DPCPX 1 mg/
kg, ADO A2 antagonist DMPX 1 mg/kg).
Table 2. Renal tissue concentrations of adenosine
Condition Compound Dose
ADO concentration
nmol/g wet wt
5.9 1.0Normoxia —
Carbon monoxide — 5.7 0.6
Carbon monoxide AOPCP 4 mg/kg 5.8 0.9
Carbon monoxide EHNA 60 umol 20.8 5.8a
Carbon monoxide solufiazinc 20 mg/kg 21.4 6.5a
Carbon monoxide dipyridamole 100 mg/kg 10.9 2.9"
Data are means ShM; N = 5 animals/group
a Significant difference from untreated controls exposed to CO (P < 0.05)
reports in which clear adenosine-synergistic and antagonistic
effects were demonstrated on different organ functions in exper-
imental animals. Thus, theophylline concentrations following sin-
gle injections at the lowest dose used in our animals were in the
range of the accepted lower effective threshold of 10 mg/mI [28].
The doses of DPCPX used in our study had a protective effect in
glycerol-induced acute renal failure, a model disease considered
to be caused by increased ADO levels in the kidney [29, 30].
Table 3. EPO concentrations, theophylline concentrations, hematocrit
and hemoglobin at the end of a 7 day treatment with theophylline
(2 mg/kg/h) or placebo (0.85% NaCI) using osmotic minipumps
(normoxic conditions)
Treatment
Drug
concentration
mg/liter
Hematocrit
%
Hemoglobin
g%
EPO
concentration
mU/mi
Placebo — 38.4 0.8 13.0 0.3 39 3.1
Theophylline 10.2 1.2 39.6 0.5 13.3 0.2 40 1.1
Data are means SEM; N = 8 animals/group.
KW-3902 had a clear beneficial effect on cephaloridine-induced
acute renal failure (as measured by creatinine clearance, kidney
histology, and proteinuria) at the lower dose used in our experi-
ments [31]. DMPX has been shown to have a maximal effect at the
dose used on NECA-induced hypothermia and locomotor activity
depression [32]. CHA and CGS 21 680 have been shown to be
active at the dose chosen [33—35]. Dipyridamole plasma concen-
trations were in the order of magnitude where an inhibition of
Theophylline
10mg/kg 50mg/kg
a e a a a a
Control
-c
Control AOPCP
Control CHA Control CGS21680
Control DPCPX Control DMPX
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ADO reuptake was demonstrated [36]. Soluflazine, which was
selected because its use is not confounded by inhibition of
phosphodiesterases as may be the case with dipyridamole, was
administered at a higher dose compared to a study by Phillips,
O'Reagan and Walter, who failed to demonstrate an effect on
interstitial ADO levels following infusion of 0.5 mg/kg [37].
AOPCP has been shown to have its maximum inhibitory effect on
5'-ectonucleotidase at a dose of 4 mg/kg about 1.5 hours after i.m.
administration [27]. EHNAwas used in the same dose as by Paul,
Rothmann and Meagher, who reported an increase in erythropoi-
etic activity in mice [38].
Second, following the application of EHNA, soluflazine and
dipyridamole we found an increase in ADO levels in whole kidney
homogenates (Table 2). Although this finding cannot prove the
local activation of ADO receptors on EPO producing cells, it
indicates that the three substances were effective in enhancing
ADO availability in the kidney. Interestingly, the measurement of
renal ADO concentrations also showed that there was no differ-
ence between ADO levels in normoxic animals and animals
exposed to carbon monoxide, indicating that the effect of this type
of hypoxia on ADO accumulation is different from renal ischemia,
which was reported to result in a two- to sixfold increase of renal
ADO levels [14, 15]. Since carbon monoxide is a very potent
stimulus for EPO production, leading to an approximately 30-fold
increase in serum hormone levels within the brief four hour
period, the conclusion that this increase in EPO production is not
mediated by a rise in ADO levels is supported further. As in a
previous study [27] AOPCP, the inhibitor of 5'-ectonucleotidase,
did not lead to a detectable reduction of basal tissue ADO levels,
although when applied under exactely the same the conditions,
AOPCP was found to inhibit the ischemia-induced rise in ADO
concentrations [27]. The contribution of 5'-ectonucleotidase to
ADO production may thus be much more significant under
conditions of increased ADO production than under basal condi-
tions.
Third, theophylline and ADO Al and A2 receptor agonists and
antagonists had no effect on hypoxia-induced EPO production,
and were also ineffective in normoxic animals. In the short-term
experiments we cannot exclude that any of the substances inves-
tigated inhibited the basal EPO production; taking into account
the stability of EPO mRNA and EPO protein, a moderate
inhibition may not become apparent within four hours. However,
the unchanged EPO levels do indicate that the modulation of
ADO does not mimick the hypoxic response.
Finally, the failure to observe an increase of hypoxia-induced
EPO serum levels with any of the ADO synergistic substances was
not due to the fact that stimulation by 0.075% CO was already
maximal, because we found a further 2.5-fold increase of EPO
levels under the same experimental conditions when the animals
were treated, such as with the beta 2 adrenoceptor agonist
salbutamol (data not shown).
In conclusion, considering the entirety of our findings obtained
with direct and indirect adenosinergic stimulatory and inhibitory
substances, it appears unlikely that an increase in ADO concen-
trations in the peritubular renal interstitium, where the EPO
producing fibroblasts are located, mediates the large hypoxia-
induced increase in production of the hormone or modulates it in
an important fashion.
These findings are in contrast to previous work, which was
interpreted to indicate an important role of ADO for EPO
production [13]. In previous in vivo experiments, however, EPO
was not directly measured, but 59Fe incorporation was used as
indicator of erythropoietic activity. In these experiments ADO
increased 59Fe incorporation and the ADO Al receptor agonist
CHA inhibited albuterol-stimulated 59Fe incorporation [39]. This
effect was blocked by high doses of theophylline (up to 80 mg/kg),
which cannot be considered to block ADO receptors only [28].
In in vitro studies using the human hepatoma cell lines Hep G2
and Hep 3B, which produce EPO in an oxygen dependent fashion
[40], the selective ADO A 1-receptor agonist CHA increased
hypoxia-induced EPO secretion at concentrations of io and 5 X
i0 M [41], but another selective ADO A-i receptor agonist,
cyclopentyladenosine inhibited [42], NECA (a non-specific ADO
agonist [43]) stimulated [44] and CGS 21 680, a selective ADO A2
receptor agonist, had no effect on EPO secretion [45]. Apart from
inconsistencies in these findings, the extent to which EPO pro-
duction in these liver cell lines reflects regulation of the hormone
in the kidney, which contributes the majority of EPO in vivo,
remains unclear.
Bakris et al first reported [17] that in humans increased
erythropoiesis after renal transplantation may be corrected by
treatment with theophylline, and they observed a decrease in EPO
levels in patients treated with theophylline. However, this has not
been confirmed unequivocally by other investigators, who have
found that in many patients theophylline is not effective [45, 46].
Noteworthy, our experiments found that theophylline not only
had no acute effect on EPO levels (Fig. 1), but also had no effect
on EPO and hemoglobin levels as well as hematocrit after seven
days of treatment (Table 2). It is important to recognize that the
mechanisms controlling EPO secretion in post-transplant eryth-
rocytosis are unknown and may well be different from those
operating in intact kidneys. In fact, in contrast to the findings by
Bakris et al, others observed no effect of theophylline on EPO
levels in normoxic healthy adults [47]. We also have recently
found no effect of theophylline and dipyridamole on EPO pro-
duction that was stimulated in healthy volunteers by phlebotomy
[24] or exposure to hypobaric hypoxia [48].
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